Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Murphy

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Journal of Virology|June 15, 2004
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatednessMario H Skiadopoulos, Stéphane Biacchesi, Ursula J Buchholz, et al.
The Journal of Infectious Diseases|March 5, 2005
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infantsRuth A Karron, Peter F Wright, Robert B Belshe, et al.
The American Journal of Tropical Medicine and Hygiene|October 29, 2009
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteersPeter F Wright, Anna P Durbin, Stephen S Whitehead, et al.
Vaccine|May 26, 2009
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adultsKawsar R Talaat, Ruth A Karron, Karen A Callahan, et al.
Vaccine|July 31, 2007
Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primatesSheila M Nolan, Mario H Skiadopoulos, Konrad Bradley, et al.
Vaccine|January 13, 2006
Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlersShabir A Madhi, Clare Cutland, Yuwei Zhu, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 12, 2015
One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrelJason C Simeone, Cliff Molife, Elizabeth Marrett, et al.
Vaccine|June 23, 2009
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adultsRuth A Karron, Kawsar Talaat, Catherine Luke, et al.
Virology|July 30, 2010
Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primatesAnne Schaap-Nutt, Christopher D'Angelo, Emerito Amaro-Carambot, et al.
The Pediatric Infectious Disease Journal|June 7, 2003
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infantsRuth A Karron, Robert B Belshe, Peter F Wright, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Journal of Virology|June 15, 2004
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatednessMario H Skiadopoulos, Stéphane Biacchesi, Ursula J Buchholz, et al.
The Journal of Infectious Diseases|March 5, 2005
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infantsRuth A Karron, Peter F Wright, Robert B Belshe, et al.
The American Journal of Tropical Medicine and Hygiene|October 29, 2009
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteersPeter F Wright, Anna P Durbin, Stephen S Whitehead, et al.
Vaccine|May 26, 2009
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adultsKawsar R Talaat, Ruth A Karron, Karen A Callahan, et al.
Vaccine|July 31, 2007
Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primatesSheila M Nolan, Mario H Skiadopoulos, Konrad Bradley, et al.
Vaccine|January 13, 2006
Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlersShabir A Madhi, Clare Cutland, Yuwei Zhu, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 12, 2015
One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrelJason C Simeone, Cliff Molife, Elizabeth Marrett, et al.
Vaccine|June 23, 2009
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adultsRuth A Karron, Kawsar Talaat, Catherine Luke, et al.
Virology|July 30, 2010
Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primatesAnne Schaap-Nutt, Christopher D'Angelo, Emerito Amaro-Carambot, et al.
The Pediatric Infectious Disease Journal|June 7, 2003
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infantsRuth A Karron, Robert B Belshe, Peter F Wright, et al.
Pageof 13